A comprehensive view of Generics/Biosimilars. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Amgen Launches Amjevita, a biosimilar to AbbVie's Humira adalimumab, in US to treat seven inflammatory diseases including moderate-to-severe rheumatoid arthritis in adults; Amjevita’s wholesale acquisition cost is 55% below current Humira list price
Published: February 02, 2023 by Mondaq Business Briefing
AmerisourceBergen serving as generic pharmaceutical firm Civica’s exclusive distribution and supply chain partner for Civica members; partnership being rolled out in phases in first half of 2023 and aims to ensure supply of generic medicines nationwide
Published: January 27, 2023 by Business Wire
AstraZeneca’s newest asthma launch fills a gap as generics chip away at respiratory flagships; company’s respiratory, inflammation sector drugs represent about 13% of AstraZeneca’s overall revenue
Published: January 24, 2023 by PharmaVoice
China in talks with Pfizer for license to allow Chinese drug makers to make genetic version of Paxlovid COVID-19 antiviral drug Reuters reports; China seeks to finalize deal by January 22 before Lunar New Year
Published: January 06, 2023 by News24 (South Africa)
Novartis to pay US$245.0M to end antitrust litigation alleging it tried to delay US launch of generic versions of its Exforge hypertension drug; CVS, Kroger, Rite Aid, Walgreens among plaintiffs in the litigation
Published: December 29, 2022 by CE Noticias Financieras (Latin America)

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count